Wedge Capital Management’s Integra LifeSciences IART Stock Holding History

Wedge Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-62,675	Closed	-$778K	–	541
2025 Q4	$778K	Sell	62,675 -2,200	-3%	-$29.2K	0.01%	455
2025 Q3	$930K	Sell	64,875 -5,239	-7%	-$71.8K	0.02%	438
2025 Q2	$860K	Buy	70,114 +801	+1%	+$11.6K	0.02%	441
2025 Q1	$1.52M	Sell	69,313 -3,236	-4%	-$76.1K	0.03%	359
2024 Q4	$1.65M	Sell	72,549 -118	-0.2%	-$2.58K	0.03%	358
2024 Q3	$1.32M	Sell	72,667 -15,222	-17%	-$353K	0.02%	384
2024 Q2	$2.56M	Sell	87,889 -20,100	-19%	-$596K	0.05%	284
2024 Q1	$3.83M	Sell	107,989 -1,778	-2%	-$71.1K	0.06%	266
2023 Q4	$4.78M	Buy	109,767 +1,832	+2%	+$72.1K	0.09%	240
2023 Q3	$4.12M	Buy	+107,935	New	+$4.54M	0.08%	245

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wedge Capital Management's IART Position: Q1 2026 in Review

Wedge Capital Management sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 62,675 shares — an estimated $778K sold.

Wedge Capital Management first reported a position in IART in Q3 2023 and held it in 10 quarters. The position peaked at $4.78M in Q4 2023. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

Wedge Capital Management reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
Wedge Capital Management sold 62,675 Integra LifeSciences shares in Q1 2026, an estimated $778K.
Wedge Capital Management first reported a position in Integra LifeSciences in Q3 2023 and held it in 10 quarters.
Wedge Capital Management's Integra LifeSciences position peaked at $4.78M in Q4 2023.
201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Wedge Capital Management's 13F filing for Q1 2026, filed 13 Apr 2026.